About Axion Biosystems
Axion Biosystems is a Healthcare company based in Atlanta (United States) founded in 2007, and was acquired by Summa Equity in July 2021. It operates as a multi-electrode array technology is developed for cellular information analysis access. Axion Biosystems has raised $20.31 million across 14 funding rounds from investors including HHS, GRA Venture Fund and Summa Equity. Axion Biosystems has completed 1 acquisition, including msolv. Its website axionbiosystems.com draws about 35 thousand monthly visits. Axion Biosystems offers products and services including MEA Maestro Pro, Omni Pro 12, and Corning Cell Counter. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its legal entity is Axion BioSystems, Inc. Its competitors include 10X Genomics, Mission Bio, Cellares, LUMICKS and LevitasBio and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Axion Biosystems was founded in 2007 in Atlanta, United States, within the biotechnology sector. Multi-electrode array technology is provided by the company to support cellular analysis in research, clinical, and drug discovery applications. Operations include the development of single-well systems, stimulating and recording channels, multi-well systems, and integrated circuits designed to reduce stimulation artifacts. Focus is placed on enabling precise data collection for scientific and therapeutic purposes.
- Headquarters Atlanta, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website axionbiosystems.com
- Social LinkedIn X YouTube
- Acquired by Summa Equity (Jul 2021)
- Legal Name Axion Biosystems, Inc
- Total Equity Funding$20.31M (USD)
in 14 rounds
- Latest Funding Round$2.82M (USD), Grant
Jan 2020
- InvestorsHHS
& 2 more
- Investments & Acquisitions
- Acquired bySumma Equity
(Jul 2021)
Products & Services of Axion Biosystems
Axion Biosystems offers a comprehensive portfolio of products and services, including MEA Maestro Pro, Omni Pro 12, and Corning Cell Counter.
Monitors electrical activity in neurons and cardiomyocytes in real time.
Provides automated live-cell imaging for cellular biology analysis.
Automates brightfield and fluorescent counting of cells and organoids.
Apps and channels of Axion Biosystems
its YouTube channel Axion BioSystems has 1.69K subscribers and 30 videos.
Videos from Axion Biosystems
The most watched videos on Axion Biosystems's YouTube channel, Axion BioSystems (1.69K subscribers). Click a video to play it here.
More on Axion BioSystems.
Funding Insights of Axion Biosystems
Axion Biosystems has successfully raised a total of $20.31M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $2.82 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.31M
- Total Rounds 14
- Last Round Grant — $2.82M
- First Round $349,674
(Jul 2008)
- Investors Count 2
Latest 10 of 14 funding rounds of Axion Biosystems with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $2.82M | Grant | – | – | |
| Sep 2018 | $8M | Series C | – | – | – |
| May 2016 | $6M | Series C | – | GRA Venture Fund | – |
| Apr 2016 | $219,965 | Grant | – | – | |
| May 2012 | $3.21M | Series B | – | – | – |
| Sep 2011 | $389,404 | Grant | – | – | |
| Aug 2011 | $389,404 | Grant | – | – | |
| Jul 2010 | $2.1M | Series A | – | – | – |
| Sep 2009 | $2.21M | Grant | – | – | |
| Aug 2009 | $556,989 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Axion Biosystems
Axion Biosystems has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, GRA Venture Fund and Summa Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed & early stage sector-agnostic venture capital firm funding companies in the US | – | graventurefund.org | Atlanta, United States | |
Summa Equity is focused on thematic and impact investments. | 2016 | summaequity.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Axion Biosystems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Axion Biosystems
38 people are tracked at Axion Biosystems (17 in leadership, 2 in board & advisors, 19 in team).
| Name | Role | Group |
|---|---|---|
Jim Ross | Chief Technical Officer | Leadership |
Todd Lewis | Senior Vice President Of Global Sales | Leadership |
Daniel Millard | Vice President, R&d - Bioelectronics | Leadership |
Andy Le | Director Of Information Technology | Leadership |
Tom O'Brien | CEO & President | Leadership |
Victoria Stahl | Senior Director, Lead Generation | Leadership |
Alex Bragg, MD, PhD | Clinical Director | Leadership |
Stacie Chvatal | Vice President Of Product Management | Leadership |
Steven Fiene | Director, Creative Marketing | Leadership |
Rika Yamazaki | Senior Marketing And Business Development Director | Leadership |
Gisele Mukunzi | Finance Director - EMEA | Leadership |
Andrew Willsie | Vice President Of Engineering And Operations | Leadership |
Peter Lindqvist | Vice President EMEA Sales | Leadership |
Shuxin Guo | Sales Director APAC | Leadership |
Saad Sheikh | Interim Group CFO | Leadership |
Alp Aras, CFA | Director Strategy Corporate Development | Leadership |
David Brunt | Operations Director UK | Leadership |
Nick Roelofs | Board Member | Board & advisors |
Gustavo Salem | Chair | Board & advisors |
Richard Blum | Principal Hardware Engineer | Team |
18 more people are available in the full profile.
Complete people profiles for Axion Biosystems
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axion Biosystems
Axion Biosystems has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include msolv.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Advanced laser and inkjet systems for manufacturing are developed. | msolv.com | Witney, United Kingdom | 2007 | Feb 2022 | •••• |
Complete acquisition details for Axion Biosystems
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Axion Biosystems
5 dated milestones of Axion Biosystems across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Axion Biosystems is founded.
- Funding First funding round of $350K.
- Funding Latest funding round, Grant, of $2.8M.
- Exit Acquired by Summa Equity.
- Acquisition Acquires msolv.
Competitors of Axion Biosystems
Axion Biosystems has 9 listed competitors in our database, 9 of them funded. They include 10X Genomics, Mission Bio, Cellares, LUMICKS and LevitasBio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| cellares.com | 2019 | San Francisco, United States | $355M | – | Medical devices for cell-based therapy manufacturing are produced. | |
| lumicks.com | 2014 | Amsterdam, Netherlands | $93.38M | – | Optical tweezers instruments for single-molecule analysis are manufactured. | |
| levitasbio.com | 2017 | San Francisco, United States | $73.77M | – | Single-cell imaging platform developed via magnetic levitation technology. | |
| biolog.com | 1984 | Hayward, United States | $33.62M | 27 | Cell-based phenotyping technologies and assays are provided for microbial analysis. | |
| xcellbio.com | 2012 | San Francisco, United States | $40.9M | 11 | Cell culture analysis devices for cancer research are developed. | |
| atrandi.com | 2016 | Vilnius, Lithuania | $31.01M | – | Microfluidic solutions for life sciences and single-cell analysis are developed. | |
| rebusbio.com | 2006 | Santa Clara, United States | $20M | – | An imaging system for single-cell gene analysis is developed. |
Detailed competitors of Axion Biosystems
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Axion Biosystems
The website of Axion Biosystems (axionbiosystems.com) receives about 35.5K visits a month.
- Monthly visits35.5K
▲ 16.2% vs previous month
Websites whose visitors overlap most with Axion Biosystems. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| multichannelsystems.com | 100% | 123.5K | #370,590 | View details | |
| mxwbio.com | 96% | 22.5K | #1,121,454 | View details | |
| bioz.com | 89% | 62.4K | #597,932 | View details | |
ced.co.uk | ced.co.uk | 88% | – | #1,464,236 | – |
| fujifilmcdi.com | 88% | 13K | #1,883,705 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Axion Biosystems
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Axion Biosystems (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Axion Biosystems
Complete news archive for Axion Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axion Biosystems
Axion Biosystems was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Axion Biosystems is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Axion Biosystems is a funded company, having raised a total of $20.31M across 14 funding rounds to date. The company's 1st funding round was a Grant of $556.99K, raised on Jul 2008.
Axion Biosystems was founded in 2007 in Atlanta, United States, within the biotechnology sector. Multi-electrode array technology is provided by the company to support cellular analysis in research, clinical, and drug discovery applications. Operations include the development of single-well systems, stimulating and recording channels, multi-well systems, and integrated circuits designed to reduce stimulation artifacts. Focus is placed on enabling precise data collection for scientific and therapeutic purposes.
Axion Biosystems's top competitors include 10X Genomics, Mission Bio and Cellares.
Axion Biosystems offers MEA Maestro Pro, Omni Pro 12, and Corning Cell Counter.
Axion Biosystems has made 1 acquisition, including msolv.
Axion Biosystems has 3 investors. Key investors include HHS, GRA Venture Fund, and Summa Equity.
Axion Biosystems operates through Axion Biosystems, Inc.
Yes. Axion Biosystems was acquired by Summa Equity in July 2021.